基因组编辑市场规模、份额和成长分析（按技术、交付方式、应用、改进和地区划分）—产业预测（2026-2033 年）

全球基因组编辑市场预计到 2024 年将达到 89.9 亿美元，到 2025 年将达到 105 亿美元，到 2033 年将达到 363.7 亿美元，在预测期（2026-2033 年）内复合年增长率为 16.8%。

全球基因组编辑市场正经历强劲成长，这主要得益于成功的临床前模型、日益激烈的竞争、基因编辑技术的进步以及农业生物技术的日益普及。基于CRISPR的工具的快速发展显着拓展了该行业在疾病检测和治疗创新方面的视野，为服务供应商在尚未开发的市场中提供了盈利机会。政府投入的增加和基因组学相关倡议的激增进一步推动了市场扩张，各公司正透过许可协议和策略合作扩大其市场份额。人工智慧的整合正在革新产业结构，透过优化CRISPR设计、加速标靶发现和最大限度地减少脱靶效应，最终提高基因修饰的精准度，并简化罕见疾病和肿瘤细胞及基因治疗的工作流程。

全球基因组编辑市场按技术、递送方式、应用、应用类型和地区进行细分。依技术划分，可分为 CRISPR/Cas9、TALEN/megaTAL、ZFN 和Meganucleases。依递送方式划分，可分为体外和体内。依应用划分，可分为基因工程和临床应用。按应用类型划分，可细分为合约开发和自主研发。按地区划分，分析涵盖北美、欧洲、亚太、拉丁美洲以及中东和非洲。

全球基因组编辑市场驱动因素

随着各国政府和私人投资者投入大量资源研发创新基因组编辑技术，以期攻克罕见疾病、癌症和遗传异常等难题，全球基因组编辑市场正经历显着成长。由美国国立卫生研究院 (NIH)主导的体细胞基因组编辑倡议(SCGEI) 等项目，以及创投对 CRISPR相关企业的创业投资投入，都在加速该领域的发展。资金的涌入使得製药公司、生技公司和学术机构能够快速开发先进的基因编辑工具和治疗平台，为基因医学领域的潜在突破创造了蓬勃发展的环境。

限制全球基因组编辑市场的因素

全球基因组编辑市场面临许多挑战，主要源自于围绕人类基因组编辑（尤其是生殖细胞系编辑）的复杂伦理考量。各地政府对CRISPR技术应用的不同监管规定阻碍了其商业化进程。诸如基因编辑婴儿争议等备受瞩目的事件，进一步加剧了公众的认知困境。因此，这些伦理困境，加上严格的法律体制和公众的不信任，导致基因组编辑技术在农业和医疗保健领域的接受度和核准缓慢。

全球基因组编辑市场趋势

在全球基因组编辑市场，开发能够提高精准度并最大限度减少脱靶效应的先进编辑技术已成为显着趋势。碱基编辑、先导编辑器以及包括Cas12和Cas13在内的CRISPR变体等创新技术，正引领更安全、更有效的基因修饰方法。这些最尖端科技无需双链即可实现逐个碱基的编辑，标誌着基因治疗方法的一个突破性转折点。尤其值得一提的是，该领域的主要企业正日益专注于先进的可程式设计编辑仪器，这表明他们更加重视客製化解决方案，而这些方案有望彻底改变治疗应用和基因研究。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球基因组编辑市场规模（依技术及复合年增长率划分）（2026-2033 年）

• （CRISPR）/Cas9
• TALENs／MegaTALs
• ZFN
• Meganucleases

全球基因组编辑市场规模（按交付方式和复合年增长率划分）（2026-2033 年）

• 体外
• 体内

全球基因组编辑市场规模（按应用及复合年增长率划分）（2026-2033 年）

• 基因工程
• 临床应用

全球基因组编辑市场规模（按类型和复合年增长率划分）（2026-2033 年）

• 合约类型
• 内部开发类型

全球基因组编辑市场规模（按地区划分）及复合年增长率（2026-2033 年）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• CRISPR Therapeutics AG
• Editas Medicine, Inc.
• Danaher Corporation
• Intellia Therapeutics, Inc.
• Sangamo Therapeutics, Inc.
• Beam Therapeutics Inc.
• Prime Medicine, Inc.
• Thermo Fisher Scientific, Inc.
• Horizon Discovery Group plc
• Synthego Corporation
• Caribou Biosciences, Inc.
• Precision BioSciences, Inc.
• Locus Biosciences, Inc.
• ToolGen, Inc.

结论与建议

Global Genome Editing Market size was valued at USD 8.99 Billion in 2024 and is poised to grow from USD 10.5 Billion in 2025 to USD 36.37 Billion by 2033, growing at a CAGR of 16.8% during the forecast period (2026-2033).

The global genome editing market is experiencing robust growth driven by successful preclinical models, heightened competition, and advancements in gene editing technologies, alongside increasing adoption of agricultural biotechnology. The rapid evolution of CRISPR-based tools has significantly broadened industry horizons for disease detection and treatment innovation, presenting lucrative opportunities for service providers in untapped markets. Rising government funding and a surge in genomics initiatives are further propelling market expansion, as companies engage in licensing agreements and strategic partnerships to enhance their presence. The integration of artificial intelligence is revolutionizing the landscape by optimizing CRISPR design, accelerating target discovery, and minimizing off-target effects, ultimately improving precision in gene modifications and streamlining workflows in cell and gene therapies for rare diseases and oncology applications.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Genome Editing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Genome Editing Market Segments Analysis

The global genome editing market is segmented into technology, delivery mode, application, mode, and region. By technology, the market is classified into (CRISPR)/Cas9, TALENs/megaTALs, ZFN, and meganucleases. Depending on delivery mode, it is divided into ex-vivo and in-vivo. According to the application, the market is bifurcated into genetic engineering and clinical applications. As per mode, it is fragmented into contract and in-house. Regionally, it is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

Driver of the Global Genome Editing Market

The Global Genome Editing market is experiencing substantial growth as both governments and private investors channel considerable resources into innovative genome editing technologies aimed at addressing rare diseases, cancer, and genetic abnormalities. Programs such as the Somatic Cell Genome Editing initiative spearheaded by the U.S. National Institutes of Health, along with significant venture capital investments in CRISPR-related companies, are accelerating progress in this field. This influx of funding is enabling pharmaceutical firms, biotechnology companies, and academic institutions to rapidly develop advanced gene-editing tools and therapeutic platforms, fostering a dynamic environment ripe for breakthroughs in genetic medicine.

Restraints in the Global Genome Editing Market

The Global Genome Editing market faces significant challenges primarily due to complex ethical considerations surrounding human genome editing, especially with germline modifications. The commercialization process encounters obstacles due to the varying regulations imposed by regional authorities regarding the use of CRISPR technology. High-profile controversies, such as those related to gene-edited babies, further complicate public perception. As a result, these ethical dilemmas, combined with stringent legislative frameworks and a general sense of mistrust among the public, are contributing to a slowdown in the acceptance and approval of genome editing technologies within both agricultural and healthcare sectors.

Market Trends of the Global Genome Editing Market

The global genome editing market is witnessing a significant trend towards the development of advanced editing technologies that enhance precision and minimize off-target effects. Innovations such as base editors, prime editors, and variations of CRISPR, including Cas12 and Cas13, are paving the way for safer and more effective gene modifications. These state-of-the-art techniques allow for single-base edits without the need for double-strand breaks, marking a pivotal shift in gene therapy approaches. Notably, leading companies in the sector are increasingly focusing on sophisticated, programmable editing devices, indicating a growing emphasis on tailored solutions that promise to revolutionize therapeutic applications and genetic research.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Genome Editing Market Size by Technology & CAGR (2026-2033)

• Market Overview
• (CRISPR)/Cas9
• TALENs/MegaTALs
• ZFN
• Mega-nucleases

Global Genome Editing Market Size by Delivery Method & CAGR (2026-2033)

• Market Overview
• Ex-Vivo
• In-Vivo

Global Genome Editing Market Size by Application & CAGR (2026-2033)

• Market Overview
• Genetic Engineering
• Clinical Applications

Global Genome Editing Market Size by Mode & CAGR (2026-2033)

• Market Overview
• Contract
• In-House

Global Genome Editing Market Size & CAGR (2026-2033)

• North America (Technology, Delivery Method, Application, Mode)
  • US
  • Canada
• Europe (Technology, Delivery Method, Application, Mode)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Technology, Delivery Method, Application, Mode)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Technology, Delivery Method, Application, Mode)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Technology, Delivery Method, Application, Mode)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• CRISPR Therapeutics AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Editas Medicine, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beam Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prime Medicine, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Discovery Group plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synthego Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caribou Biosciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Precision BioSciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Locus Biosciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ToolGen, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations